E-LIB Suche - Ergebnisse für: Katayama Yuki

1

AXL signal mediates adaptive resistance to KRAS G12C inhibi..:

Morimoto, Kenji ; Yamada, Tadaaki ; Hirai, Soichi...
Cancer Letters. 587 (2024) - p. 216692 , 2024

Link: https://doi.org/10.1016/..

2

Nationwide data from comprehensive genomic profiling assays..:

Ishida, Masaki ; Iwasaku, Masahiro ; Doi, Toshifumi...
Cancer Science. 115 (2024) 5 - p. 1656-1664 , 2024

Link: https://doi.org/10.1111/..

3

Rapid and high throughput assessment of cellular immunity a..:

Saito, Taro ; Couzinet, Arnaud ; Murakami, Taku...
Biochemical and Biophysical Research Communications. 694 (2024) - p. 149398 , 2024

Link: https://doi.org/10.1016/..

4

Comparing Three Different Anti–Programmed Death-Ligand 1 An..:

Katayama, Yuki ; Yamada, Tadaaki ; Morimoto, Kenji...
JTO Clinical and Research Reports. 5 (2024) 3 - p. 100644 , 2024

Link: https://doi.org/10.1016/..

5

Efficacy and Safety of Docetaxel plus Ramucirumab for Patie..:

Onoi, Keisuke ; Yamada, Tadaaki ; Morimoto, Kenji...
Targeted Oncology. 19 (2024) 3 - p. 411-421 , 2024

Link: https://doi.org/10.1007/..

6

Prospective Observational Study of Ramucirumab Plus Docetax..:

Katayama, Yuki ; Yamada, Tadaaki ; Sawada, Ryo...
The Oncologist. 29 (2024) 5 - p. e681-e689 , 2024

Link: https://doi.org/10.1093/..

7

Clinical usefulness of the "GeneSoC® SARS-CoV-2 N2 Detectio..:

Sato, Yuki ; Kondo, Takashi ; Katayama, Yuki...
Journal of Laboratory Medicine. 48 (2024) 2 - p. 91-95 , 2024

Link: https://doi.org/10.1515/..

8

TTF-1 Expression and Clinical Outcomes of Combined Chemoimm..:

Katayama, Yuki ; Yamada, Tadaaki ; Morimoto, Kenji...
JTO Clinical and Research Reports. 4 (2023) 4 - p. 100494 , 2023

Link: https://doi.org/10.1016/..

9

Chemoimmunotherapy Versus Pembrolizumab as a First-Line Tre..:

Morimoto, Kenji ; Yamada, Tadaaki ; Kawachi, Hayato...
Targeted Oncology. 18 (2023) 6 - p. 915-925 , 2023

Link: https://doi.org/10.1007/..

10

Predictive Value of Modified Glasgow Prognostic Score and P..:

Tanimura, Keiko ; Takeda, Takayuki ; Yoshimura, Akihiro...
Cancers. 15 (2023) 17 - p. 4358 , 2023

Link: https://doi.org/10.3390/..

11

Clinical Efficacy and Safety of First- or Second-Generation..:

Morimoto, Kenji ; Yamada, Tadaaki ; Takeda, Takayuki...
Targeted Oncology. 18 (2023) 5 - p. 657-665 , 2023

Link: https://doi.org/10.1007/..

12

Effects of Combined Therapeutic Targeting of AXL and ATR on..:

Hirai, Soichi ; Yamada, Tadaaki ; Katayama, Yuki...
Molecular Cancer Therapeutics. 23 (2023) 2 - p. 212-222 , 2023

Link: https://doi.org/10.1158/..

13

Dasatinib attenuates airway inflammation of asthma exacerba..:

Nishimoto, Yuki ; Ando, Daiki ; Irie, Kosuke...
Biochemistry and Biophysics Reports. 33 (2023) - p. 101402 , 2023

Link: https://doi.org/10.1016/..

14

Fluorinated 2,6-Xylenesulfonyl Group: A Protective Group fo..:

Katayama, Yuki ; Watanabe, Kenta ; Nishiyama, Yoshitake.
Organic Letters. 25 (2023) 8 - p. 1326-1330 , 2023

Link: https://doi.org/10.1021/..

15

Adaptive resistance to lorlatinib via EGFR signaling in ALK..:

Katayama, Yuki ; Yamada, Tadaaki ; Tanimura, Keiko...
npj Precision Oncology. 7 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..